当前位置:首页 > 报告详情

Dexcom-JPMorgan-Conference-Deck_Shared-Master_FINAL.pdf

上传人: 明**** 编号:1069711 2026-01-17 25页 4.86MB

1、CONFIDENTIAL DO NOT DISTRIBUTEJANUARY 12,2026ConferenceHealthcareJ.P.Morgan2This presentation contains“forward-looking statements”that are based on our managements beliefs and assumptions and on information available to management as of January 12,2026.We intend for such forward-looking statements t

2、o be covered by the safe harbor provisions for forward-looking statements contained in the U.S.Private Securities Litigation Reform Act of 1995.Forward-looking statements include information concerning our possible or assumed strategy,future operations,financing plans,operating model,future operatin

3、g results and financial position,including estimated revenue,organic revenue growth,non-GAAP gross profit margin,non-GAAP operating margin,and Adjusted EBITDA margin for fiscal year 2025,projected costs,competitive position and the effects of competition on our business,industry environment,potentia

4、l growth opportunities,potential market opportunities,and the plans and objectives of management.This presentation also contains estimates and other statistical data made by independent parties relating to market size and growth and other data about our industry.This data involves a number of assump

5、tions and limitations,and you are cautioned not to give undue weight to such estimates.Forward-looking statements include all statements that are not historical facts and can be identified by terms such as“anticipates,”“believes,”“could,”“seeks,”“estimates,”“targets,”“guidance,”“expects,”“intends,”“

6、may,”“plans,”“potential,”“predicts,”“prospects,”“projects,”“should,”“will,”“would”or similar expressions and the negatives of those terms,although not all forward-looking statements contain these identifying words.Forward-looking statements involve known and unknown risks,uncertainties and other fac

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **业绩与增长**:2025年营收约46.62亿美元,有机增长约15%,活跃用户超350万,2026年营收指引51.6-52.5亿美元(增长11-13%)。 2. **市场地位**:全球CGM行业先驱,美国市场覆盖超2500万患者,渗透率Type 1达60-65%,Type 2 IIT达55-60%,仍有900万未覆盖患者。 3. **产品创新**:G7 15天延长佩戴,MARD准确率8.0%;Stelo OTC CGM用户超50万,2025年营收1.3亿美元;G8研发中(体积缩小60%)。 4. **财务目标**:2026年非GAAP毛利率63-64%,运营利润率22-23%,调整后EBITDA超15亿美元,自由现金流超10亿美元。
**Dexcom增长动力?** **CGM市场前景?** **创新技术突破?**
客服
商务合作
小程序
服务号
折叠